Citations

Clear

396 citation(s) found for "Spinner, M".

Selective peripheral denervation for refractory cervical dystonia: a single-center retrospective analysis of 160 cases
Porche, Ken, Hayford, Kirsten M., Spinner, Robert J., Barone, Damiano G, Barone, Damiano G. , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 5 | Pages: 1154-1162

10.3171/2025.8.jns2592 | PMID 41569713 Get It

OBJECTIVE Cervical dystonia (CD) is the most common focal dystonia, characterized by abnormal head postures and pain, often refractory to botulinum toxin therapy. Selective peripheral denervation (SPD) remains a key surgical option, but long-term outcomes in large cohorts are underreported. The purpose of this study was to evaluate the long-term outcomes of SPD in patients with botulinum toxin–refractory CD, focusing on symptom severity, pain, and head posture improvement. METHODS This retrospective study included 160 adults (mean ± SD age 54 ± 12.0 years, 46% male) with refractory CD who underwent SPD at a single center by a single surgeon from January 2005 to July 2023. Outcomes were assessed using subjective clinical measures and the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), which was calculated retrospectively from clinical records. The modified Bertrand technique involved selective denervation and myotomies tailored to each patient’s dystonic pattern. TWSTRS scores were analyzed at baseline, 3 months, 1 year, and final follow-up (mean ± SD 10.3 ± 9.0 months). Time to minimal clinically important difference (MCID) (≥ 12-point TWSTRS drop) was evaluated with covariate-adjusted Kaplan-Meier modeling (ever vs never revised, evaluated with the log-rank test) and a counting-process Cox model with revision as a time-dependent covariate. RESULTS Among 160 patients (mean follow-up duration 21.6 ± 35.6 months), TWSTRS improved by 73.5% at 3 months and 61.3% at last follow-up (p < 0.001). Median time to MCID was 3.0 months for never revised patients versus 22.0 months for ever revised patients (log-rank chi-square statistic = 19.09, p < 0.0001). In a time-dependent Cox model, revision surgery was significantly associated with higher likelihood of achieving MCID (HR 2.31, p < 0.005). Pain relief and improved head posture were reported in over 50% of patients. Complications were minimal, and recurrence was observed in 4.2% of cases. Outcomes were consistent with or exceeded those reported in the literature with either SPD or deep brain stimulation (DBS). CONCLUSIONS SPD is an effective and durable surgical option for refractory CD, significantly improving pain, posture, and quality of life. Although revision surgery delayed time to improvement, it significantly increased the likelihood of achieving meaningful clinical improvement. Overall efficacy aligns with the existing literature, reinforcing its role as a first-line surgical intervention. Further studies should explore strategies to enhance long-term outcomes and delineate the role of SPD relative to DBS.
Core outcomes in nerve surgery: development of a core outcome set for lateral femoral cutaneous neuropathy
Wilson, Thomas J., Ali, Zarina S., Desai, Ketan, Garozzo, Debora, Guedes, Fernando, Heinen, Christian P. G., Hong, Jennifer , Jacques, Line G., Jitpun, Ekkapot , Kretschmer, Thomas , Mahan, Mark A., Midha, Rajiv, Puffer, Ross C. , Rasulic, L., Ray, Wilson Z., Rizk, Elias , Rodriguez-Aceves, Carlos A., Shapira, Yuval, Spinner, Robert J., Zager, Eric L. , Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Dengler, Nora F. , Guedes, Fernando , Heinen, Christian , Jacques, Line , Mahan, Mark A , Midha, Rajiv, Pondaag, Willem , Rasulić, Lukas , Ray, Wilson Z. , Rodríguez-Aceves, Carlos Alberto , Saadeh, Yamaan S. , Socolovsky, Mariano , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | January 22, 2026 | Volume: 144 | Issue: 5 | Pages: 1224-1232

10.3171/2025.8.jns251142 | PMID 41569664 Get It

OBJECTIVE Core outcome sets (COSs) are needed to promote data consistency across studies as well as data synthesis and comparability. The aim of the current study was to use a modified Delphi process to develop a COS for lateral femoral cutaneous neuropathy (LFCN), hereafter COS-LFCN. METHODS A 5-stage approach was used to develop the COS-LFCN: 1) consortium development, 2) literature review to identify potential outcome measures, 3) Delphi survey to develop consensus on outcomes for inclusion, 4) Delphi survey to develop definitions, and 5) consensus meeting to finalize the COS and definitions. This study followed the Core Outcome Set - STAndards for Development, (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 25 participants, all neurological surgeons, representing 14 countries. The final COS-LFCN consisted of 41 factors and outcomes covering domains of demographics, diagnostics, patient-reported outcomes, motor/sensory outcomes, and complications. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 12 months, with the consensus optimal time points for assessment being preoperatively and 3, 6, and 12 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS for LFCN and provided definitions, methods of implementation, and time points for assessment. The COS-LFCN should serve as the minimum data to be collected in all future neurosurgical studies on LFCN. Incorporation of this COS will help improve consistency in reporting, data synthesis and comparability, and minimize outcome reporting bias.
Metachronous ganglion cysts: illustrative case
Spinner, Robert J., Howe, B. Matthew, Reiser, Daniel , Spinner, Robert J , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | January 22, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.3171/case25618 | PMID 41569739 Get It

BACKGROUND Ulnar neuropathy at Guyon’s canal is rare, but when it occurs, it is frequently due to underlying masses, including extraneural and intraneural ganglion cysts, as well as adventitial cysts. The pathogenesis of these cysts, especially at a rare site, remains controversial. The articular theory, which is gaining popularity, posits that a joint connection via a nerve (or vascular) branch to a neighboring joint represents the pathway for their formation and propagation. OBSERVATIONS A recently published case of a patient with an ulnar intraneural ganglion at the wrist with a series of postoperative cystic recurrences was reevaluated, as it challenged the articular theory. No discrete articular branch had been identified on imaging or at surgery. Serial MR images were reinterpreted, which revealed that the original intraneural cyst was treated; new sequential cysts—an adventitial cyst and then a soft tissue ganglion—developed, all arising from the same wrist joint. LESSONS This case strengthens the principles of the articular theory for intraneural ganglion, adventitial, and soft tissue ganglion cysts. A small wrist connection from the ulnar intraneural ganglion was unrecognized and untreated. Scarring disrupted the original nerve pathway and pressure dynamics. New cysts developed through neighboring joint capsular rents along different pathways into other “compartments” (vessel or soft tissues). https://thejns.org/doi/10.3171/CASE25618
Circumferential subparaneurial ganglion cyst involving the ulnar nerve at the elbow: illustrative case
Ruiter, Godard C W de, Amrami, Kimberly K. , Reina, M A, Son, Byung-chul , Spinner, Robert J., Reina, Miguel Ángel , Reina, Miguel Angel , Spinner, Robert J , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery: Case Lessons | January 22, 2026 | Volume: 10 | Issue: 25 | Pages: No page available

10.3171/case25671 | PMID 41569763 Get It

BACKGROUND Recently, the distribution of subparaneurial ganglion cysts involving the common peroneal and tibial nerves was described based on MRI analysis. Crossover in extreme cases was observed at the sciatic bifurcation through a mechanism comparable to a geyser, enabled by fenestrations in the epi- and paraneurium at the level of the bifurcation. The goal of this study was to investigate whether the geyser theory for crossover holds for other locations. OBSERVATIONS The authors’ prospectively maintained database of > 1100 cases of intraneural ganglion cysts in the world’s literature was queried for the existence of subparaneurial ganglion cysts at locations other than the knee. A previously unrecognized case involving the ulnar nerve originating from the elbow joint was found. Reinterpretation of the patient’s MRI studies showed circumferential subparaneurial distribution of a cyst over a long distance. Based on their previously reported geyser theory, the authors wondered if crossover had occurred at the level of the medial cord. A fenestration in the epi- and paraneurium at this level was confirmed on histological analysis of a normal cadaveric specimen. LESSONS This illustrative case shows that the geyser theory also holds in other locations. Surgical treatment of these subparaneurial cysts still follows the principles of the unified articular theory. https://thejns.org/doi/10.3171/CASE25671
The Scarlet Letter of the Unmatched Neurosurgery Reapplicant: Trends, Opinions, and Guidance from a Nationwide Survey
Cole, Kyril L. , Sagher, Oren , Pham, Martin H. , Cook, Steven, Cole, Chad , Spinner, Robert J. , Murad, Gregory J. A. , Couldwell, William T. , Jensen, Randy L. , Group, the Unmatched Applicants Study, Van Gompel, Jamie, Couldwell, William T , Gompel, Jamie J. Van , Group, the Unmatched Applicants Study

Mayo Clinic

Journal of the American College of Surgeons | December 17, 2025 | Volume: 242 | Issue: 6 | Pages: 1517-1528

10.1097/xcs.0000000000001737 | PMID 41404973 Get It

BACKGROUND: Increasing interest in neurosurgery residency has led to a growing number of unmatched applicants, who often struggle to find appropriate guidance for their next steps. The authors examined trends, opinions, and options available to unmatched neurosurgery residency reapplicants. STUDY DESIGN: Demographic data of US applicants from MD programs obtained from the National Resident Matching Program (2009 to 2024) were analyzed using 1-way ANOVA analysis of time-interval averages. Opinions about reapplicants were assessed via an online survey of national neurosurgery leaders, including residency program directors and chairpersons (N = 356). RESULTS: All application trends showed greater change over time; however, the rate of accepted reapplicants showed no significant change among early (2009 to 2013: 4.8 ± 1.8), mid (2014 to 2018: 7.6 ± 4.8), and recent periods (2019 to 2024: 9.8 ± 2.5; p = 0.068). The survey had a 23.0% response rate (82 of 356). Commonly indicated reasons for failure to match included poor interview skills, weak recommendation letters, and personality issues. Although most survey respondents supported candidates reapplying, dual applications (applying to more than 1 specialty) were not widely encouraged. For those reapplying, pursuing a preliminary general surgery or research fellowship, obtaining new letters of recommendation from new subinternships, and publishing higher-quality research were the most endorsed uses of time before reapplying. However, most programs reported interviewing reapplicants sometimes to rarely and matching a reapplicant rarely to never. CONCLUSIONS: The number of reapplicants successfully matching into neurosurgery has not changed significantly during the past 15 years. Surveys indicate that leaders view reapplicants unfavorably, despite reapplicants’ efforts to improve their applications. These results suggest that neurosurgery mentors may do a disservice to potential reapplicants based on how residency program leadership considers reapplications. Candid guidance is needed for reapplicants in the residency matching process.
Outcomes of second line platinum salvage and autologous stem cell transplant compared to CD19 CAR-T in patients with Relapsed/Refractory primary mediastinal B-cell lymphoma: A multi-center, retrospective analysis
Yang, Xi , Dumke, Henry, Lanka, Sree M , Okcu, Izel, Nowakowski, Grzegorz, Doukas, Peter , Colton, Meryl D. , Pizzuti, V., Adewale, Olutobi, Baron, Kelsey, Bock, Allison M. , Karimi, Yasmin , Pizzuti, Vincenzo J. , Karimi, Yasmin H , Okcu, Izel , Pizzuti, Vincenzo J , Schroers‐Martin, Joseph G. , Sawalha, Yazeed , Nowakowski, Grzegorz, Karmali, Reem , Spinner, Michael A. , Pizzuti, Vincenzo, Kamdar, Manali , Adewale, Olutobi, Tiger, Yun Kyoung , Geer, Marcus

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 783-783

10.1182/blood-2025-783 Get It

Abstract Introduction: Primary mediastinal B-Cell lymphoma (PMBCL) is a rare form of large B-Cell lymphoma (LBCL) with around 90% of patients (pts) cured with first line (1L) treatment. For pts with relapsed or refractory (RR) PMBCL, the optimal treatment is unclear. Prior retrospective analysis in the rituximab (R) era have shown high response rates to platinum salvage and high-dose chemotherapy followed by autologous stem cell transplant (HDT/ASCT) in second line (2L) RR PMBCL (Bakos et al. ASH 2023 and Dumke et al. ASCO 2024). The pivotal phase III LBCL trials in early relapsing pts that compared CD19 chimeric antigen receptor-T cell (CAR-T) with HDT/ASCT as 2L treatment had few PMBCL pts: none on ZUMA-7 and 17 PMBCL on TRANSFORM, of whom only 8 were randomized to 2L CAR-T. This study aims to evaluate outcomes of 2L therapies for RR PMBCL, including pts treated with 2L CAR-T. Methods: We performed a multicenter retrospective study in pts with RR PMBCL treated between 2001 and 2025. Clinical and pathologic characteristics, treatment regimens, and efficacy outcomes were collected and analyzed. Results: 139 pts were included with 43% male, 69% Caucasian, 7.9% Black, 8.6% Asian and 79% Non-Hispanic. R-EPOCH (64%) and (32%) were the most common 1L treatments and all pts received R. Consolidative radiation was used in 21 pts (15%) as part of 1L therapy, 28% after RCHOP. Primary refractory disease with relapse ≤6 month (mo), or early relapse ≤12 mo, occurred in 83% (N = 115) and 93% (N = 129 pts), respectively. At relapse, median age was 34 years (yrs), 44% had advanced stage disease, 31% had bulky disease (≥ 7.5cm). CNS relapse occurred in 8.6% of pts. Overall and complete response rate (ORR and CR) to any 2L treatment was 44% and 27%, respectively. At median follow-up of 40 months (mo) from the start of 2L treatment, median PFS of the entire cohort was 3.2 mo with a 3 yr OS of 70%. For 2L treatment, N=93 (67%) pts were treated with platinum salvage with intention to proceed with HDT/ASCT. Most commonly used platinum salvage regimens were ICE± R (n= 53, 38%), R-DHAP (n=23, 17%), R-GemOx (n= 5, 3.6%), and GDP ± R (n= 10, 7.2%), and the majority (95%) of pts received R with 2L therapy. ORR and CR to platinum salvage was 46% and 15% respectively. With a median follow up of 30 mo from start of 2L therapy, median PFS was 2.6 mos, and 3 yr PFS and OS was 15% and 64%, respectively. Of the 93 pts treated with platinum salvage, only 25 pts (27%) proceeded with HDT/ASCT- of whom, N = 17 (68%) achieved a CR after ASCT. In patients that proceeded to ASCT, relapses occurred in 10 pts (40%) with a 3 yr PFS and OS 56% and 83%, respectively. CAR-T was used as 2L in 20 pts (14%)- most commonly either axi-cel (N =7) or liso-cel (N = 8). ORR and CR to CART was 89% and 55% respectively, median PFS and OS was NR after CAR-T infusion and 3 yr PFS and OS was 55% and 95%, respectively. Other 2L treatments included pembrolizumab (N =3), brentuximab vedotin (BV) + nivolumab (N= 4) or single agent BV (N=2). Radiation was given as part of 2L treatment in 25.9% of pts. 2L CAR-T therapy was associated with improved ORR (OR 7.60, 95% CI 1.68 – 34.55, p = 0.002), improved CR rate (OR 4.15, 95% CI 1.49 – 11.53, p = 0.008) and improved PFS (HR 0.18, 95% CI 0.06 – 0.57, p = 0.004) compared to pts treated with 2L platinum salvage. There was no difference in OS between pts treated with platinum salvage or 2L CAR-T. A total of 96 patients progressed on 2L therapy, and 92 pts (95.8%) received third-line (3L) treatment. Third line treatments included chemoimmunotherapy +/- HDT/ASCT (N= 23), CD19 CAR-T (N = 35), clinical trial (N=7), check point inhibitor-based regimen (N= 11), BV based regimen (N= 8), allogeneic stem cell transplant (N = 3) or other (N = 5), with 7 pts receiving radiation as part of 3L therapy. Median PFS and OS from start of 3L therapy was 6.7 mo and 6.4 mo, respectively. Conclusions: We report the largest cohort of pts with RR PMBCL treated in the rituximab era and the largest number of PMBCL pts treated with 2L CAR-T. This is the first analysis, to our knowledge, to show a statistically significant benefit in PFS, ORR and CR rate of CAR-T compared to platinum salvage followed by HDT/ASCT as 2L treatment in a study of exclusively RR PMBCL pts. Our dataset was largely (93%) compromised of pts with primary refractory or early relapsing disease and provides support for using CAR-T as 2L treatment in this high-risk subset of RR PMBCL patients.
Gene therapy in three classical hematological disorders – is social media making a difference?
Khera, Anika, Pruthi, Rajiv K. , Padrnos, Leslie , Wolanskyj-Spinner, Alexandra P., Shah, Surbhi , Khera, Anika, Go, Ronald S. , Godby, Richard , Sridharan, Meera , Wolanskyj, Alexandra P.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 7844-7844

10.1182/blood-2025-7844 Get It

Abstract Gentically driven classical hematological disorders have variable prevelance in the general population, sickle cell disease (SCD) being the most common at 30 per 100,000 people, hemophilia (hem) 12 per 100,000 people for hemophilia A, 4 per 100,000 people for hemophilia B, and thalassemia (thal) at 18 per 100,000 people, with regional and racial-ethnic variation across US. There has been a dramatic change in the therapeutic landscape for these diseases in the past decade. Several new drugs and biological therapies including gene therapies have been approved for each of these disorders. Clinicians utilize different information sources to assimilate this rapid influx of knowledge into their practice; in the era of social media, the readership is not limited to original publications. As research visibility influences clinical adoption and patient awareness, it is vital to understand the modalities of engagement of gene therapy studies by clinicians and patients. An altmetric score is a simple and effective way of understanding engagement with research across platforms. It. measures digital attention received by research output, allowing us to gauge the social impact of an article. We sought to compare the impact and scientific dissemination of publications of gene therapy trials in these 3 diseases by capturing the number of traditional citations and Altmetric assessment score. Methods: A PubMed search was conducted for gene therapy trials in SCD, Hem and Thal between 2015 to 2025 and citations were captured using metrics from Google Scholar. The Altmetric assessment score for each article was determined using www.altmetric.com which includes any mention by news outlets, blogs, Twitter (X), Facebook, and Mendeley reader counts. Descriptive statistics are reported for the number of citations as well as the Altmetric assessment score in each of the disease categories. Median and range were reported due to the skewed distribution of the data. Comparison across groups for significance was done using the Kruskal-Wallis test. Results: The number of qualifying studies for SCD (n=7) were lower than hem (n=21) and thal (n=12). Median PubMed citations were highest for SCD (147, range 4-436), followed by hem (26, range 0-828) and thal (42, range 0-801), though the difference was not statistically significant (p=0.4) Altmetric scores demonstrated differences that approached statistical significance with p=0.08: SCD had the highest median (422, range 4-770), driven by exceptional Twitter engagement, while hem and thal medians were 20 (range 0-2038) and 49 (range 0-825) respectively. Twitter/X was the leading social platforms for all diseases. Scholarly interest measured by Mendeley readers was also highest for SCD (median 195, range 11-542), with thal and hem medians at 50 (range 0-773) and 64 (range 8-646) respectively. Conclusion: We observed substantial variability in both academic and social media dissemination of practice-changing SCD, Hem and thal gene therapy studies, though not statistically significant likely due to the limited number of studies overall. Higher citation count and Altmetric score in SCD studies may reflect recent robust dissemination efforts by ASH and patient advocacy groups. Intentional promotion across academic and media platforms increases awareness, helping with early dissemination of updated information that could have significant impact on patient outcomes.
Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic
Adeoye, Oluwatayo , Yousuf, Muhammad , King, Rebecca L. , Ivana, Micallef, Spinner, Robert J. , Nowakowski, Grzegorz S. , Khurana, Arushi , Johnston, Patrick, Falade, Ayo , Bolarinwa, Abiola , Rosenthal, Allison , Tsang, Mazie , Iqbal, Madiha , Lachance, Daniel Honore , Wang, Yucai , Habermann, Thomas M.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 6306-6306

10.1182/blood-2025-6306 Get It

Abstract Background Neurolymphomatosis (NL) is a rare and frequently underrecognized manifestation of lymphoma, characterized by infiltration of peripheral or cranial nerves by malignant lymphocytes. Limited data exist to guide optimal management. We present the largest single-enterprise (included the 3 Mayo Clinic sites) cohort to date, evaluating disease characteristics, treatment patterns, and outcomes in patients (pts) with NL. Methods We conducted a retrospective analysis of pts ≥18 years (yrs) diagnosed with clinical, radiographic, or biopsy-confirmed NL at Mayo Clinic between January 2002 and December 2024. Baseline characteristics were compared using independent t-tests for continuous variables and Fisher's exact or Pearson's chi-square tests for categorical variables. Primary endpoints were overall survival (OS) and progression-free survival (PFS). Objective response rate (ORR) was a secondary endpoint. Kaplan–Meier methods, log-rank tests, and Cox proportional hazards regression were used to assess survival outcomes and associated factors. Results We included 149 pts. Median age at diagnosis was 64 yrs (range 22–83), and 23% were female. Most presented with stage IV disease (89%), and NL was part of the initial lymphoma presentation in 42% (primary NL). Diagnostic confirmation was based on histopathology and imaging in 55%, imaging alone in 26%, histopathology alone in 16%, and clinical features in 4%. Diffuse large B-cell lymphoma was the most common histology (61%), followed by marginal zone lymphoma (7%), and T-cell lymphoma (7%). Clinical presentation included painful neuropathy (65%), concurrent CNS involvement (37%), systemic disease (43%), elevated LDH (46.9%), and ECOG ≥2 (38%). Pattern of involvement included cranial nerves (29%), peripheral nerves (28%), and spinal nerve roots (27%). Median follow-up was 92 months (95% CI, 63–119). Among 137 treatment-evaluable pts, first-line regimens included methotrexate-based (MTX) (62%), bendamustine-based (B) (11%), cytarabine-based (Ara-C) (4%), and rituximab-based (R) (excluding MTX, B, or Ara-C) (15%) therapies. Radiation was used in 18%, and 21% underwent autologous stem cell transplant (ASCT). Among 103 response-evaluable pts, the ORR was 67% (52% complete response [CR], 16% partial response [PR]). ORRs by regimen were 78% (MTX), 92% (B), and 86% (R). On univariate analysis, primary NL (OR 4.3) and frontline ASCT (OR 8.47) were associated with higher odds of response (p&lt;0.05), while ECOG ≥2 (OR 0.24) and localized disease (OR 0.33) were associated with lower odds. On multivariable analysis (MVA), primary NL (OR 5.0 [1.5–12.1], p=0.02) and ECOG &gt;1 (OR 0.2 [0.06–0.79], p=0.018) remained significant predictors of response. Median PFS was 13 months (95% CI, 9–36), with a 2-yr PFS of 43% (95% CI, 35–53). On MVA, concurrent CNS involvement (HR 2.4, p=0.05), systemic disease (HR 2.7, p=0.02), and ECOG &gt;1 (HR 2.4, p=0.02) were associated with inferior PFS, while primary NL was associated with improved PFS (HR 0.3, p=0.002). Patients undergoing frontline ASCT had a median PFS of 108 months (95% CI, 58–not reached) with a 7-yr PFS of 62% (95% CI, 46–84). Among those receiving second line and beyond (2+) therapy, 24 received MTX-based regimens, 10 received CAR-T, and 8 received tyrosine kinase inhibitors. Post-ASCT median PFS was 30 months (95% CI, 15–NR). Among CAR-T recipients, evaluable responses (n=8) included 4 CR, 1 PR, and 3 PD. Median OS was 56 months (95% CI, 29–133), with a 5-yr OS of 50% (95% CI, 41–60). On MVA, ECOG ≥2 (HR 2.5, p=0.02) predicted worse OS, while receipt of ASCT (HR 0.4, p=0.04) and primary NL (HR 0.5, p=0.04) were associated with improved OS. Conclusion This study represents the largest single-enterprise cohort of pts with NL, providing comprehensive insight into its clinical presentation, treatment patterns, and outcomes. Primary NL and preserved PS were independently associated with improved response rates and survival, while CNS and systemic involvement at diagnosis portended poorer PFS. MTX and bendamustine-based regimens achieved high ORR, and frontline ASCT was associated with significantly prolonged remission duration and OS. These findings highlight the prognostic importance of baseline disease burden and functional status, support the early incorporation of high-intensity regimens in eligible patients, and underscore the urgent need for prospective studies to guide evidence-based management in this rare and understudied population.
Multicenter real-world outcomes in limited stage (LS) diffuse large B-cell lymphoma (DLBCL) treated with abbreviated immunochemotherapy
Cherng, Hua-Jay, Gerber, Drew, Nze, Chijioke, Bhayani, Shahzeem, Russler-Germain, David, Alnughmush, Ahmed, Hampel, Paul, Kille, Kelsey, Wallace, Danielle, Qualls, David, Merryman, Reid, Brooks, Jaden, Bock, Allison, Ramirez, Juan, Zhang, Yumeng, Chavez, Julio, Granger, Katelynn, Antel, Katherine, Duarte, Cassandra, Major, Ajay, Ma, Sirui, Spinner, Michael, Mackay, Alyssa, Hu, Bei, Rai, Manoj, Spurgeon, Stephen, Lee, Benjamin, Doh, Jean, Brem, Elizabeth, Altomare, Nicole, Karmali, Reem, Ryan, Robert, Tiger, Yun Kyoung, Carter, Jordan, Landsburg, Daniel, Thiruvengadam, Swetha, Skarbnik, Alan, Choi, Yun, Bond, David, Samaeekia, Ravand, Ma, Helen, Tolu, Seda, Amengual, Jennifer, Herrera, Alex, Pro, Barbara, Qualls, David , Qualls, David A , Cherng, Hua-Jay, Gerber, Drew, Nze, Chijioke, Bhayani, Shahzeem, Russler-Germain, David, Alnughmush, Ahmed, Hampel, Paul, Kille, Kelsey, Wallace, Danielle, Merryman, Reid, Brooks, Jaden, Bock, Allison, Ramirez, Juan, Zhang, Yumeng, Chavez, Julio, Granger, Katelynn, Antel, Katherine, Duarte, Cassandra, Major, Ajay, Ma, Sirui, Spinner, Michael, Mackay, Alyssa, Hu, Bei, Rai, Manoj, Spurgeon, Stephen, Lee, Benjamin, Doh, Jean, Brem, Elizabeth, Altomare, Nicole, Karmali, Reem, Ryan, Robert, Tiger, Yun Kyoung, Carter, Jordan, Landsburg, Daniel, Thiruvengadam, Swetha, Skarbnik, Alan, Choi, Yun, Bond, David, Samaeekia, Ravand, Ma, Helen, Tolu, Seda, Amengual, Jennifer, Herrera, Alex, Pro, Barbara

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 471-471

10.1182/blood-2025-471 Get It

Abstract Background: For LS-DLBCL, clinical trials (FLYER, LYSA/GOELAMS 02-03, LYSA LNH09-1B, S1001) have shown that 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (RCHOP4) without radiation (RT) leads to durable remissions in &gt;90% of cases. However, only patients (pts) with non-bulky disease and/or international prognostic index (IPI) of 0 and complete metabolic response (CMR) on interim positron emission tomography (PET) scan, if performed, were eligible for RCHOP4 alone in these studies. Outcomes in trial-ineligible LS-DLBCL and the appropriate real-world candidates for RCHOP4 are still undefined. Methods: We conducted a multicenter retrospective study of adult pts with stage I/II DLBCL of any tumor bulk, IPI and with or without B-symptoms diagnosed after 2011 and treated with RCHOP4 +/- 2 cycles R from 21 U.S. centers. Pts with PMBCL, PTLD or receiving non-standard dose RCHOP for cycle (C) 1 or planned consolidative RT were excluded. The primary endpoint was PFS from C1 by Kaplan-Meier method, not counting indolent lymphoma relapse. Event free survival (EFS) was time to next therapy without progression (including unplanned RT for non-CR), progression or death. A competing risks analysis of non-relapse mortality (NRM) vs. DLBCL progression was performed. Results: The characteristics of the 428 pts were: median age 60 (18-88), 60% male, 11% Hispanic and 4% non-Hispanic Black, 62% stage I, 15% elevated LDH, 3% ECOG PS&gt;1, 5% tumor bulk &gt;7cm, 9% had B-symptoms and median Charlson Comorbidity Index (CCI) was 4 (2-12). IPI was 0, 1 and 2-3 in 42%, 46% and 12% and stage-modified IPI (smIPI) was 0, 1, 2 and 3-4 in 25%, 48%, 21% and 6% of pts. 66% had nodal (59% head/neck, 11% pelvic, 9% multiple above diaphragm, 7% abdominal) and 46% extranodal sites (37% head/neck, 20% gastric/intestinal, 9% spleen, 8% skin/soft tissue); 6% had transformed/concurrent FL/MZL or grade 3B FL, 33% (138/408) were non-GCB cell of origin (COO), 25% (90/357) double expressor (DEL) and 0.5% (2/379) double-hit. 13% had completely resected disease, 97% staging PET and 47% bone marrow biopsy. Median diagnosis to treatment interval was 30 days (IQR 20-43), 6% had dose reductions after C1, 77% had an interim PET (iPET) after C2 (33%) or C3 (67%), 15% received 2 additional cycles R and 4% CNS prophylaxis. CMR rates by iPET were 83% after C2 and 94% after C3, and 95% by end-of-treatment PET. iPET PMR was more likely if smIPI&gt;2 or bulky disease. Median follow-up time was 2.7 years. There were 32 progression events: 14 occurred at the primary site and 17 at distant sites (1 unknown), and 12 occurred after 2 years. Another 11 pts received unplanned RT after RCHOP4 for non-CR. There were 24 deaths, 12 without prior progression. Cause of death was DLBCL in 7 and non-DLBCL in 17 cases (6 infection, 2 ILD, 2 heart failure, 2 second cancer, 1 seizure, 4 unknown). EFS, PFS and OS rates were 88%, 90% and 96% at 3 years. By univariable Cox regression, Black race, elevated LDH, smIPI&gt;2, DEL, increasing CCI, multiple subdiaphragmatic nodal sites and iPET PMR were associated with worse PFS. Non-significant variables of note included COO, extranodal sites, complete resection, missing bone marrow biopsy, missing iPET and additional cycles R. By multivariable analysis (including age&gt;60, stage, ECOG PS&gt;1, elevated LDH, bulky disease, CCI, B-symptoms and DEL), ECOG PS&gt;1 (HR 3.95 p=0.050), CCI (HR 1.29 p=0.003) and DEL (HR 2.02 p=0.069) were associated with worse PFS. Cumulative incidence of DLBCL progression and NRM were 8% and 2% at 3 years. Competing risk analysis by univariable models found that age&gt;60, ECOG PS&gt;1, smIPI&gt;2, elevated LDH, CCI and bulky disease were associated with NRM, while DEL and B-symptoms were associated with DLBCL progression.Conclusion: Presented is the largest retrospective cohort of LS-DLBCL treated uniformly with RCHOP4 to date. Despite modest follow-up time and lack of an “intention-to-treat“ population, this study shows that abbreviated RCHOP4 leads to excellent outcomes in the real-world, albeit with continuous risk of late relapse. smIPI risk factors were associated with worse PFS, though this may in part be driven by risk of non-lymphoma death. As pts with advanced age, poor performance status or comorbidities may benefit from reduced treatment exposure, RCHOP4 should still be considered for these and other “trial-ineligible” pts, particularly if other high-risk features (iPET PMR, DEL or B-symptoms) are absent.
Malignant peripheral nerve sheath tumors in schwannomatosis: a case series
Hayford, Kirsten M., Gui, Chloe , Suppiah, Suganth , Spinner, Robert J., Porche, Ken M. , Spinner, Robert J.

Mayo Clinic

Journal of Neurosurgery | November 15, 2025 | Volume: 144 | Issue: 3 | Pages: 633-641

10.3171/2025.6.jns25872 | PMID 41237389 Get It

OBJECTIVE Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas predominantly associated with neurofibromatosis type 1 (NF1). However, their occurrence within NF type 2 (NF2)–related and SMARCB1-related schwannomatosis remains rare and poorly characterized. Accurate and timely diagnosis is challenging due to clinical and radiological similarities with benign schwannomas, potentially delaying appropriate management and impacting outcomes. This study presents an institutional case series aiming to better characterize the clinical presentations specifically for MPNSTs arising in patients with NF2- and SMARCB1-related schwannomatosis. METHODS This retrospective case series included patients diagnosed with schwannomatosis who subsequently developed histopathologically confirmed MPNSTs. Conducted at Mayo Clinic (Rochester, Minnesota) and University Health Network (Toronto, Canada), the study spanned January 1, 2003, to November 1, 2024. Patients were selected based on clinical or genetic diagnoses of schwannomatosis using International Consensus Group on Neurofibromatosis Diagnostic Criteria. Comprehensive clinical, radiological, and pathological data, including demographics, presenting symptoms, tumor features (size, location, immunohistochemistry, genetics), treatments (resection, chemotherapy, radiotherapy), and follow-up outcomes were extracted from electronic medical records. RESULTS The authors identified 8 patients with a mean age of 36 years, half of whom had NF2-related schwannomatosis. The most common presenting symptom was pain (71%). The mean tumor size was 8.2 ± 7.0 cm, with gross-total resection being the most common surgical treatment (67%), typically supplemented with radiation therapy (78%). More than half of the patients (56%) exhibited metastatic disease, and all tumors with reported grading were Fédération Nationale des Centres de Lutte Contre le Cancer grade 3. No tumors were associated with LZTR1 mutations. One notable case involved a 39-year-old male with SMARCB1-related schwannomatosis who had a femoral MPNST resected 13 years prior and subsequently developed a sciatic nerve MPNST that was managed successfully with neoadjuvant chemotherapy, radiation therapy, and negative margin resection. Of note, the second lesion arose from a hybrid neurofibroma/schwannoma. Another case, a 33-year-old male with SMARCB1-related schwannomatosis, had an incidental finding of epithelioid MPNST in a minimally symptomatic small palmar lesion. CONCLUSIONS This case series highlights that MPNSTs, although uncommon, can arise in NF2- and SMARCB1-related schwannomatosis without prior radiation exposure, presenting significant diagnostic challenges due to their similarity to benign schwannomas. The findings underscore the importance of maintaining clinical vigilance and employing individualized management strategies, balancing thorough resection with the preservation of function and patient quality of life.